Related Experiment Video
Updated: May 18, 2026
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Cell-Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer
Nami Tamura1, Takashi Hirayama1, Emiko Yoshida1
1Department of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
Introduction:
Ascites management is crucial for gynecological cancer patients requiring long-term treatment. Cancer type-specific differences may influence CART outcomes, but comparative data remain limited. This study evaluated CART efficacy in gynecological versus other cancers.
Methods:
This subgroup analysis included 125 cancer patients undergoing 296 CART sessions at 22 Japanese centers (2014-2015). Patients were divided into gynecological cancer (Group G, n = 46) and other cancer groups (Group O, n = 79).
Results:
Group G had significantly higher concurrent chemotherapy rates (41.2% vs. 12.3%, p < 0.001) and ascitic protein/albumin concentrations. Group G showed significant renal function improvements: decreased serum creatinine (0.7 ± 0.3 to 0.6 ± 0.3 mg/dL, p < 0.001), decreased BUN (17.9 ± 8.7 to 14.5 ± 9.0 mg/dL, p < 0.001), and increased eGFR (72.7 ± 24.8 to 81.3 ± 27.6 mL/min/1.73 m2, p < 0.001). Drainage intervals were longer in Group G (20.0 ± 13.8 vs. 11.7 ± 10.9 days, p < 0.001).
Conclusion:
CART demonstrates enhanced efficacy in gynecological cancer patients, particularly improving renal function, potentially reducing chemotherapy-related toxicity, and improving treatment tolerability.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...